PMC9036436_01
The flowchart of the case timeline to illustrate the diagnosis and treatment.
fonc-12-808801-g001.jpg
PMC9036436_02_fonc-12-808801-g001.jpg
f1
The PFS of olaparib plus etoposide was 5.9 months, the overall survival was 19 months ( Figure 1 ).
PMC9036436_02
The flowchart of the case timeline to illustrate the diagnosis and treatment.
fonc-12-808801-g001.jpg
PMC9036436_02_fonc-12-808801-g001.jpg
f1
The PFS of olaparib plus etoposide was 5.9 months, the overall survival was 19 months ( Figure 1 ).
CT imaging showing the recurrent masses and the change of these masses after therapy. Masses after recurrence (A-C); The recurrent masses kept stable after 1 cycle of etoposide (D-F); The recurrent masses were obviously shrunk after 2 cycles of etoposide-olaparib (G-I); These masses kept stable after 4 cycles (J-L) and 6 cycles (M-O) of etoposide-olaparib.
fonc-12-808801-g002.jpg
PMC9036436_02_fonc-12-808801-g002.jpg
f2
A CT scan revealed a 2.0cm mass in the paraaortic lymph node ( Figure 2A ), a 3.0 cm mass in the subcarinal lymph node ( Figure 2B ), and a large mass (8.9 cm) in the left lung hilar area ( Figure 2C ). After 1 cycle, CT showed similar size masses as before, the efficacy was stable ( Figures 2D-F  vs.  Figures 2A-C ). After 2 cycle of olaparib plus etoposide, CT scans showed marked shrinking of the masses ( Figures 2G-I ), the efficacy reached to partial response. A CT scan performed on 19th December 2018, after 4 cycles of treatment, revealed that the masses were well controlled ( Figures 2J-L ). The patient continued to use this regimen, with further CT scans (on 15th February 2019) showing that the masses were still under control ( Figures 2M-O ).